[Neuroimmune aspects of the pathogenesis and nitric oxide negative effects modifying the pathogenetic treatment of tick-borne infections].
Patients with different forms of infections transmitted by Ixodidae ticks: meningeal and focal forms of tick-borne encephalitis, neuroborreliosis and mixed-infection (tick-borne encephalitis + Ixodidae tick borreliosis) were examined. CD-typing of lymphocytes in the cerebral spinal fluid (CSF), measuring blood and CSF cytokine content as well as blood nitric oxide (NO) metabolites were used to identify main pathogenetic mechanisms of the immune inflammation development in the central nervous system in tick-borne encephalitis associated with the hyperproduction of NO metabolites in the blood and CSF, inflammatory cytokine reaction and apoptosis. The antioxidant cytoflavin is suggested as a drug for pathogenetic treatment of neuroinfections with modifying effect of NO. The significantly rapid reduction (p<0.05) of general brain, focal brain and neuropsychological disorders as well as the decrease (p<0.05) in the endogenous hyperproduction of NO metabolites were found in patients (n=35) who received cytoflavin compared to those (n=35) who did not receive this drug. The authors recommend to use the drug in dose 10.0 ml once a day intravenously in drops during 7 − 10 days.
A B
AB
Kon'kova-Reĭdman
L I
LI
Ratnikova
D000328:Adult; D000818:Animals; D015415:Biomarkers / Q000032:analysis / Q000097:blood / Q000134:cerebrospinal fluid; D002490:Central Nervous System / Q000276:immunology*; D016207:Cytokines / Q000032:analysis / Q000097:blood / Q000134:cerebrospinal fluid; D004338:Drug Combinations; D004675:Encephalitis, Tick-Borne / Q000188:drug therapy* / Q000276:immunology*; D005260:Female; D005486:Flavin Mononucleotide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007290:Inosine Diphosphate / Q000008:administration & dosage / Q000627:therapeutic use*; D018884:Ixodes / Q000382:microbiology; D020852:Lyme Neuroborreliosis / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D009536:Niacinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D009569:Nitric Oxide / Q000096:biosynthesis; D013386:Succinates / Q000008:administration & dosage / Q000627:therapeutic use*
D015415:Biomarkers; D016207:Cytokines; D004338:Drug Combinations; D018696:Neuroprotective Agents; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D009569:Nitric Oxide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate